Therapeutic Asset Ratings

1,028 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
hlx43 Small Cell Lung Carcinoma	Shanghai Henlius Biotech	P2	CCC (48)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide Gastric Cancer	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CCC (48)
immunoglobulin G1-kappa, anti-[Homo sapiens CDH6(cadherin 6, K-cadherin (foetal kidney), cadherin 6 type 2)], humanized monoclonal antibody conjugated to deruxtecan, comprising a linker and a camptothecin derivative Non-Small Cell Lung Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (48)
Ladiratuzumab Vedotin Breast Neoplasm	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Ladiratuzumab Vedotin Her2-Receptor Negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Loncastuximab Tesirine High Grade B-Cell Lymphoma	Universität Münster	P2	CCC (48)
Mirvetuximab Soravtansine-GYNX Fallopian Tube Cancer	University of Colorado, Denver	P2	CCC (48)
rc48-adc Colon Cancer	The First Affiliated Hospital of Zhengzhou University	P2	CCC (48)
rc48-adc Metastatic Prostate Carcinoma	The First Affiliated Hospital of Xiamen University	P2	CCC (48)
Sacituzumab Tirumotecan Her2-Receptor Negative Breast Cancer	Fudan University	P2	CCC (48)
Shr-A2009 Her2-Receptor Negative Breast Cancer	Fudan University	P2	CCC (48)
Trastuzumab Deruxtecan Glioblastoma	Memorial Sloan Kettering Cancer Center	P2	CCC (48)
Trastuzumab Duocarmazine Breast Neoplasm	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Trastuzumab Duocarmazine Her2-Receptor Negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Trastuzumab Emtansine Glioblastoma	Patrick Wen, MD	P2	CCC (48)
Trastuzumab Emtansine Lung Cancer	Memorial Sloan Kettering Cancer Center	P2	CCC (48)
Zirconium Zr 89 Crefmirlimab Berdoxam Melanoma	ImaginAb, Inc.	P2	CCC (48)
Zirconium Zr 89 Crefmirlimab Berdoxam Renal Cell Carcinoma	ImaginAb, Inc.	P2	CCC (48)
Anti-EGFR Antibody-drug Conjugate MRG003 Cancer	Shanghai Miracogen Inc.	P1/2	CCC (48)
APAMISTAMAB-B10-ASTATINE AT-211 Acute Lymphoblastic Leukemia	Fred Hutchinson Cancer Center	P1/2	CCC (48)
APAMISTAMAB-B10-ASTATINE AT-211 Acute Myeloid Leukemia	Fred Hutchinson Cancer Center	P1/2	CCC (48)
Cetuximab Sarotalocan Skin Squamous Cell Carcinoma	Rakuten Medical, Inc.	P1/2	CCC (48)
Cetuximab Sarotalocan Metastatic Head-and-neck Squamous-cell Carcinoma	Rakuten Medical, Inc.	P1/2	CCC (48)
Cetuximab Sarotalocan Head And Neck Squamous Cell Carcinoma	Rakuten Medical, Inc.	P1/2	CCC (48)
Datopotamab Deruxtecan Additional Indications Below for Module 4 and 5	AstraZeneca	P1/2	CCC (48)

Showing 626 to 650 of 1,028 assets

PreviousPage 26 of 42Next